Product Description
A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cixutumumab)
Mechanisms of Action: IGF Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Pancreatic Cancer|Sarcoma, Ewing|Liposarcoma|Primitive Neuroectodermal Tumors|Leiomyosarcoma|Non-Small-Cell Lung Cancer|Adenocarcinoma|Neurofibrosarcoma|Gliosarcoma|Osteosarcoma|Prostate Cancer|Synovial Sarcoma|Peripheral Neuroectodermal Tumors, Primitive|Hemangiosarcoma|Alveolar Soft Part Sarcoma|Embryonal Rhabdomyosarcoma|Squamous Cell Carcinoma|Alveolar Rhabdomyosarcoma|Head and Neck Cancer|Breast Cancer|Colorectal Cancer|Hepatocellular Carcinoma|Adrenocortical Carcinoma|Male Breast Cancer|Liver Cancer|Neuroendocrine Carcinoma|Small Cell Lung Cancer|Kidney Cancer|Esophageal Cancer|Soft Tissue Cancer|Gastrointestinal Cancer|Neuroblastoma|Uveal Melanoma|Bronchiolo-Alveolar Adenocarcinoma|Large Cell Carcinoma|Neuroendocrine Tumors|Hepatoblastoma|Retinoblastoma|Wilms Tumor|Rhabdomyosarcoma|Embryonal Carcinoma|Peritoneal Cancer|Mesothelioma
Phase 1: Sarcoma, Ewing|Oncology Solid Tumor Unspecified|Peripheral Neuroectodermal Tumors, Primitive|Primitive Neuroectodermal Tumors|Paraganglioma|Pancreatic Cancer|Anemia|Glioma|Carcinoid Tumor|Carcinoma, Merkel Cell|Medullary Carcinoma|Neuroendocrine Tumors|Neutropenia|Hypertension|Thrombocytopenia|Islet Cell Carcinoma|Glucagonoma|Hyperglycemia|Insulinoma|Gastrointestinal Cancer|Pinealoma|Carotid Body Tumor|Somatostatinoma|Neuroendocrine Carcinoma|Gastrinoma|Malignant Carcinoid Syndrome|Hepatocellular Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCI-2011-03039 | P2 |
Completed |
Squamous Cell Carcinoma|Head and Neck Cancer |
2018-08-15 |
|
| BATTLE-FL | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2017-08-15 |
|
| NCI-2011-01917 | P2 |
Completed |
Small Cell Lung Cancer |
2016-11-15 |
|
| 10-C-0146 | P2 |
Completed |
Peritoneal Cancer|Mesothelioma |
2016-08-13 |